Platelet-Derived Mediators in Hospitalized COVID-19 Patients with 60-Day Outcomes

245 hospitalized COVID-19 patients had plasma levels of eight platelet-derived mediators measured. The data, authored by Kari Otterdal and last updated in March 2026, examines associations with respiratory failure, ICU admission, and 60-day mortality, with follow-up measurements at three, six, and twelve months for a subpopulation.

Use Cases

• Predicting ICU admission or respiratory failure risk based on P-selectin levels.
• Modeling 60-day mortality risk using levels of PF4/CXCL4, ENA-78/CXCL5, and NAP-2/CXCL7.
• Analyzing long-term platelet activation persistence by tracking sCD40L, ENA-78/CXCL7, and VEGF-A levels up to 12 months post-hospitalization.
• Investigating in vitro platelet response to SARS-CoV-2 by modeling dose-dependent mediator release.

Strengths

• Includes data from 245 hospitalized COVID-19 patients.
• Longitudinal follow-up data for a subpopulation at three, six, and twelve months post-hospitalization.
• Measures eight specific platelet-derived mediators (e.g., RANTES, P-selectin, VEGF-A).

Limitations

• The dataset is very small at 32.8 KB, indicating limited scope.
• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.

Provenance

Source

figshare, author Kari Otterdal.

Collection Method

Plasma levels of mediators were measured in patient cohorts and in vitro experiments with isolated platelets.

Time Range

Study period not specified; includes follow-up measurements up to 12 months post-hospitalization.

Freshness

Last updated 2026-03-17 13:04:46